Novo Nordisk Faces Class Action Lawsuit Over Alleged Securities Violations

Berger Montague PC has filed a class action lawsuit against Novo Nordisk A/S (NYSE: NVO) alleging securities violations. The lawsuit was filed after Novo lowered its sales and profit guidance for the second half of fiscal 2025, citing persistent use of compounded GLP-1s, slower-than-expected market expansion, and increased competition for Wegovy and Ozempic. Novo's stock price plummeted 21% in response. Investors who purchased Novo securities between May 7, 2025, and July 28, 2025, may seek to be appointed as a lead plaintiff representative of the class by September 30, 2025.

Novo Nordisk A/S (NYSE: NVO), a global pharmaceutical company, is facing a class action lawsuit after it lowered its sales and profit guidance for the second half of fiscal 2025. The lawsuit, filed by Berger Montague PC, alleges securities violations and seeks recovery for investors who purchased Novo securities between May 7, 2025, and July 28, 2025.

On July 29, 2025, Novo announced a reduction in its sales and profit outlook, citing persistent use of compounded GLP-1s, slower-than-expected market expansion, and increased competition for its blockbuster drugs, Wegovy and Ozempic. The company's stock price dropped by more than 21% in response to the news, from $69.00 to $53.94 per share [1].

The class action lawsuit alleges that Novo understated the impact of the personalization exception to the compounded GLP-1 exclusion, allowing the persistent use of compounded alternatives to Novo’s pharmaceutical products. The lawsuit also claims that Novo overstated the likelihood of patients switching to its branded products, thus overstating the company's ability to sustain long-term growth [2].

Investors who purchased Novo securities during the specified class period are encouraged to seek appointment as a lead plaintiff representative of the class. The deadline for investors to take action is September 30, 2025 [3].

Berger Montague PC, a national plaintiffs' law firm, has a history of representing individual and institutional investors in complex securities litigation. The firm has offices in Philadelphia, Minneapolis, Delaware, Washington, D.C., San Diego, San Francisco, Chicago, Malvern, PA, and Toronto [4].

References:
[1] https://www.prnewswire.com/news-releases/berger-montague-pc-announces-class-action-filed-against-novo-nordisk-as-nyse-nvo-for-alleged-securities-violations-302522214.html
[2] https://www.morningstar.com/news/pr-newswire/20250805ny43827/lost-money-on-novo-nordisk-asnvo-join-class-action-suit-seeking-recovery-contact-levi-korsinsky
[3] https://www.globenewswire.com/news-release/2025/08/04/3126821/0/en/Berger-Montague-PC-Investigating-Claims-on-Behalf-of-Novo-Nordisk-A-S-NYSE-NVO-After-Class-Action-Filing.html
[4] https://www.berger-montague.com